Jeffrey PharmD - Nutriband Warrant Chief Officer
| NTRBW Stock | USD 1.90 0.34 21.79% |
Executive
Jeffrey PharmD is Chief Officer of Nutriband Warrant
| Age | 54 |
| Address | 121 South Orange Avenue, Orlando, FL, United States, 32801 |
| Phone | 407 377 6695 |
| Web | https://www.nutriband.com |
Nutriband Warrant Management Efficiency
The company has return on total asset (ROA) of (0.3013) % which means that it has lost $0.3013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6041) %, meaning that it generated substantial loss on money invested by shareholders. Nutriband Warrant's management efficiency ratios could be used to measure how well Nutriband Warrant manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.15 in 2024. Return On Capital Employed is likely to drop to -0.78 in 2024. At this time, Nutriband Warrant's Total Current Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 220.6 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| William Grossman | Arcus Biosciences | 50 | |
| Stephen Young | Arcus Biosciences | 55 | |
| Jim MBA | Fate Therapeutics | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Holli Kolkey | Arcus Biosciences | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Sohanya MBA | Karyopharm Therapeutics | 41 | |
| Timothy MBA | Caribou Biosciences | 55 | |
| Stuart Poulton | Karyopharm Therapeutics | N/A | |
| Cindy Tahl | Fate Therapeutics | 51 | |
| Cameron Peters | Karyopharm Therapeutics | 64 | |
| Carolyn JD | Arcus Biosciences | 45 | |
| Jennifer MBA | Arcus Biosciences | 53 | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Amy CFA | Caribou Biosciences | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Daniel Poon | Caribou Biosciences | N/A | |
| Elhan CFA | Karyopharm Therapeutics | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Jerome Bressi | Fate Therapeutics | N/A | |
| Andrew Henry | Fate Therapeutics | 60 | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.3 |
Nutriband Warrant Leadership Team
Elected by the shareholders, the Nutriband Warrant's board of directors comprises two types of representatives: Nutriband Warrant inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nutriband. The board's role is to monitor Nutriband Warrant's management team and ensure that shareholders' interests are well served. Nutriband Warrant's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nutriband Warrant's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Ryan, Chief Officer | ||
| Tyler Overk, President Intelligence | ||
| Gerald Goodman, CFO Officer | ||
| Alan Smith, COO Therapeutics | ||
| Michael Myer, President Pharmaceutical | ||
| Serguei Melnik, President Founder | ||
| Gareth Sheridan, CEO Founder | ||
| Jeffrey PharmD, Chief Officer |
Nutriband Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nutriband Warrant a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (4.62) % | ||||
| Number Of Shares Shorted | 1.03 K | ||||
| Revenue | 2.09 M | ||||
| EBITDA | (5.12 M) | ||||
| Net Income | (5.49 M) | ||||
| Cash And Equivalents | 304.26 K | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 241.28 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nutriband Stock Analysis
When running Nutriband Warrant's price analysis, check to measure Nutriband Warrant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nutriband Warrant is operating at the current time. Most of Nutriband Warrant's value examination focuses on studying past and present price action to predict the probability of Nutriband Warrant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nutriband Warrant's price. Additionally, you may evaluate how the addition of Nutriband Warrant to your portfolios can decrease your overall portfolio volatility.